Retatrutide

Plain-English answer: retatrutide is an experimental weekly injection designed to help people lose a large amount of weight and improve blood sugar and liver health. It is made by Eli Lilly and is still being tested in clinical trials — it is not something a doctor can prescribe yet.

The reason it has attracted so much attention is its design. Your gut naturally releases hormones after you eat that tell your brain you are full, help your pancreas release insulin, and influence how your body burns energy. Retatrutide is a lab-made molecule that mimics three of these hormone signals at once by activating their receptors:

• GLP-1 (glucagon-like peptide-1) — the appetite-and-fullness signal, the same target as semaglutide (Ozempic/Wegovy).
• GIP (glucose-dependent insulinotropic polypeptide) — a second gut hormone that also improves how the body handles fat and insulin; tirzepatide (Mounjaro/Zepbound) adds this one.
• Glucagon — a hormone that, among other things, increases the rate at which the body burns energy and helps the liver clear out stored fat. This is the third target, and it is what makes retatrutide different from everything already on the market.

Because it hits all three, retatrutide is called a "triple agonist" (an agonist is simply a molecule that switches a receptor on). It is administered as a once-weekly subcutaneous injection — a shot into the fat layer just under the skin — and its development code is LY3437943.

The idea behind combining these three signals is not new marketing; it comes from published science. A 2015 study in Nature Medicine first showed in rodents that a single balanced GLP-1/GIP/glucagon molecule could reduce body weight, improve blood sugar, and reverse fatty liver more effectively than molecules hitting only one or two of those targets.^[4] Retatrutide is the human realization of that concept, and it has since moved through human Phase 2 trials into Phase 3.

Where it stands today: retatrutide is investigational. As of 2026 it is in Phase 3 development (Lilly's TRIUMPH obesity program and TRANSCEND type 2 diabetes program, plus cardiovascular outcome trials). There is no approved product and no announced brand name. If you see "retatrutide" for sale outside a clinical trial, understand that it is an unregulated research chemical of unverified identity and purity — not the clinical-grade drug Lilly studies. For the broader regulatory picture, see Are Peptides Legal?

Plain-English takeaway: retatrutide fights excess weight from both directions at once — it turns down how much you eat and turns up how much energy you burn. Most weight-loss drugs only do the first half.

Each of the three receptors it activates contributes something distinct. Here is what each one does and why it matters.

GLP-1 receptor: appetite and blood sugar

• Reduces appetite through signaling in the hypothalamus, the brain's hunger-control center.
• Slows gastric emptying, so food leaves the stomach more slowly and you feel full longer.
• Stimulates the pancreas to release insulin only when blood sugar is high (a "glucose-dependent" effect, which is why it rarely causes low blood sugar on its own).

This is the same core mechanism as semaglutide and is the foundation of the whole drug class.

GIP receptor: insulin sensitivity and tolerability

• Improves how fat tissue responds to insulin and how the body processes dietary fat.
• Adds to the fullness signal alongside GLP-1.
• May help buffer the nausea that pure GLP-1 activation can cause, improving tolerability.

This is the second mechanism tirzepatide added, and it is part of why dual agonists outperformed the single-target drugs before them.

Glucagon receptor: the differentiator

• Increases energy expenditure — the body burns more calories, including at rest.
• Directly stimulates the liver to oxidize (burn off) stored fat, which is the mechanism behind retatrutide's dramatic liver-fat results.

On its own, glucagon can raise blood sugar (that is its job in a fasting emergency). The clever part of retatrutide's design is that the GLP-1 and GIP arms, which push insulin and lower glucose, are balanced against the glucagon arm so that net blood-sugar control still improves. The glucagon component adds the "burn more energy" side of the equation without letting glucose run away — at least at the doses tested in Phase 2.

Combining intake reduction (GLP-1/GIP) with increased expenditure and hepatic fat-burning (glucagon) is why the triple-agonist concept was expected to outperform single- and dual-agonist drugs. That expectation was first demonstrated in rodents^[4] and then, importantly, confirmed in the human Phase 2 trials described below. It is worth being precise about evidence levels: the mechanism story rests partly on animal work, but the weight, blood-sugar, and liver-fat results come from randomized human trials.

Plain-English takeaway: in human trials retatrutide produced record weight loss, strong blood-sugar improvement, and near-complete reversal of fatty liver. Unlike most peptides on this site, these benefits rest on real, published, randomized human trials — not just animal data. What is not yet known is the long-term picture: whether the benefits hold up over years and whether the safety trade-offs are acceptable at scale.

Record-setting weight loss (Phase 2 obesity trial)

The pivotal evidence is a randomized, double-blind, placebo-controlled Phase 2 trial published in the New England Journal of Medicine in 2023. It enrolled 338 adults with obesity (body-mass index of 30 or higher, or 27 or higher with a weight-related health condition) who did not have type 2 diabetes, and followed them for 48 weeks.^[1]

Weekly dose	Mean weight change at 48 weeks
Placebo	-2.1%
1 mg	~-8.7%
4 mg	-17.1%
8 mg	-22.8%
12 mg	-24.2%

How to read this: the average person on the 12 mg dose lost roughly a quarter of their entire body weight in under a year — the largest mean weight loss reported in any controlled anti-obesity trial to date.^[1] Two caveats keep this honest. First, "mean" is an average; individual results varied widely. Second, and importantly, the 12 mg weight-loss curve had not plateaued at 48 weeks, meaning participants were still losing weight when the trial's primary window ended. That is unusual and encouraging, but it also means the true long-term average is not yet known.

Blood-sugar control (Phase 2 type 2 diabetes trial)

A companion Phase 2 trial published in The Lancet in 2023 studied 281 adults with type 2 diabetes over 36 weeks, using dulaglutide (an established GLP-1 drug) as an active comparator rather than just placebo.^[2] At the highest dose, retatrutide:

• Lowered HbA1c — a blood test reflecting average blood sugar over about three months — by roughly 2.0 percentage points, among the larger reductions reported for any diabetes drug.
• Reduced body weight by about 17% over the 36-week study.
• Outperformed the dulaglutide comparator on both blood-sugar and weight outcomes.

Beating an already-effective active drug (not just a sugar-pill placebo) is a meaningfully stronger result than beating placebo alone.

Liver fat (MASLD Phase 2a sub-study)

A sub-study published in Nature Medicine in 2024 looked at 98 participants who had metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD — essentially excess fat stored in the liver) with at least 10% liver fat at baseline. Liver fat was measured directly by MRI, and the primary endpoint was at 24 weeks.^[3]

Weekly dose	Relative liver-fat reduction (24 wks)	Reached normal liver fat (<5%)
Placebo	+0.3%	—
8 mg	-81.4%	79%
12 mg	-82.4%	86%

Plain-English: the higher doses cut the amount of fat in the liver by more than four-fifths, and most participants reached a normal, healthy liver-fat level within 24 weeks — results that substantially exceed what current fatty-liver treatments achieve. The mechanism is the glucagon arm, which directly drives the liver to burn off stored fat; pure GLP-1 drugs do not do this directly. Reassuringly, no new liver-toxicity signal was seen through 48 weeks.^[3] (One precise note, because the internet often gets it wrong: the 82.4% reduction and 86% resolution figures are the 12 mg values at 24 weeks, not the 8 mg values.)

Honest limitations of the benefit evidence

• The core evidence is Phase 2 — mid-size, mid-length trials. Phase 3 trials (larger, longer, with harder outcomes like heart attacks and strokes) are still reading out.
• Longest primary follow-up in these trials was 48 weeks. Durability over years, and weight regain after stopping, are not yet characterized for retatrutide specifically.
• Cross-drug comparisons to semaglutide and tirzepatide come from separate trials in different populations, so head-to-head superiority is inferred, not proven by a single direct trial.
• None of this applies to unregulated "research" retatrutide, which is not the clinical-grade molecule and carries no guarantee of identity, dose, or purity.

Plain-English takeaway: in the trials, retatrutide was a once-weekly shot whose dose was raised gradually over about three months to let the body adjust and limit nausea. There is no approved dose, no approved product, and nothing here is a recommendation to use an unregulated compound — it is a description of what researchers did in controlled studies.

Doses studied

The Phase 2 trials tested four weekly subcutaneous doses — 1 mg, 4 mg, 8 mg, and 12 mg — against placebo.^[1] The 1 mg dose behaved more like a starting/titration step than a full therapeutic dose; the 8 mg and 12 mg arms produced the largest effects and are the most likely Phase 3 maintenance targets.

Weekly dose	Role in the trials	Mean weight loss (48 wks)
1 mg	Low / titration-level dose	~-8.7%
4 mg	Lower maintenance	-17.1%
8 mg	Higher maintenance	-22.8%
12 mg	Highest studied	-24.2%

Why titration matters

Retatrutide is not started at its target dose. Because the GLP-1, GIP, and glucagon effects together place a real burden on the gut, the trials escalated the dose in steps — roughly every four weeks — so that reaching 12 mg took on the order of three months. Starting high without titration sharply increases nausea, vomiting, and diarrhea. If a step is not tolerated, the standard approach is to hold at the current dose longer before advancing rather than push through.

Administration basics (as used in trials)

• Route: subcutaneous injection (into the fat under the skin) — abdomen, thigh, or upper arm, rotating sites.
• Frequency: once weekly, ideally the same day each week for even spacing.
• Timing: any time of day, with or without food.

Reconstitution math (worked example)

Research-market retatrutide is sold as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before it can be measured — this is the same arithmetic used for any peptide, and getting it wrong is one of the most common and dangerous mistakes. The formula is simple:

concentration (mg/mL) = powder in vial (mg) ÷ water added (mL)

Worked example. Suppose a vial contains 10 mg of powder and you add 1 mL of bacteriostatic water:

• Concentration = 10 mg ÷ 1 mL = 10 mg/mL.
• On a standard U-100 insulin syringe, 1 mL = 100 "units," so each unit holds 10 mg ÷ 100 = 0.1 mg (100 mcg) per unit.
• To draw a 4 mg dose: 4 mg ÷ 10 mg/mL = 0.4 mL = 40 units.
• To draw an 8 mg dose: 8 mg ÷ 10 mg/mL = 0.8 mL = 80 units.

Add water slowly down the inside wall of the vial rather than blasting it onto the powder, swirl gently until dissolved (do not shake), and label the vial with the date and concentration. Our peptide calculator and bacteriostatic water calculator do this math for you, and the reconstitution guide walks through the steps. Again: this describes the arithmetic, not an endorsement of using an unapproved compound.

Cycle length and drug interactions

Unlike some peptides, retatrutide is not "cycled" — in the trials it was taken continuously, and weight regain is expected after stopping, consistent with the whole GLP-1 class. Because it markedly slows gastric emptying, it can alter the absorption of oral medications; in a clinical setting this warrants care with oral contraceptives, levothyroxine, and narrow-therapeutic-index drugs, and dose reduction of insulin or sulfonylureas to avoid low blood sugar. These are decisions for a prescribing clinician, not for self-experimentation.

Plain-English takeaway: the most common problems are stomach-related — nausea, diarrhea, and vomiting — and they were worst while the dose was being raised. The signal that most distinguishes retatrutide from its cousins is a dose-dependent increase in resting heart rate, whose long-term meaning is not yet settled. No unexpected deaths or major safety surprises appeared in Phase 2, but Phase 2 is not large or long enough to rule out rarer or slower risks.

Most common side effects (Phase 2)

The dominant adverse events were gastrointestinal and dose-dependent — that is, more frequent at higher doses and during titration.^[1]

• Nausea — the most common effect; typically mild-to-moderate, worst during dose escalation, easing with a stable dose.
• Diarrhea — usually mild-to-moderate and transient.
• Vomiting — more common at the 8 mg and 12 mg doses and during titration.
• Decreased appetite — expected, and part of how the drug works rather than a true adverse event.
• Constipation — from slowed gastric motility.

The heart-rate signal

Across the Phase 2 program, retatrutide produced a dose-dependent increase in resting heart rate — on the order of several beats per minute at the higher doses.^[1][2] Small heart-rate increases are seen across the GLP-1 class, but the effect appears somewhat larger with retatrutide, plausibly related to the added glucagon activity. Why it matters: whether this translates into any long-term cardiovascular harm — or is offset by the benefits of large weight loss — cannot be answered by a 48-week trial. That is exactly what the ongoing Phase 3 cardiovascular outcome trials are designed to determine. Until those data exist, anyone with arrhythmia, structural heart disease, or uncontrolled hypertension has clear reason for caution.

Liver safety

Encouragingly, the MASLD sub-study found no new hepatotoxicity (liver-injury) signal through 48 weeks — reassuring given that the drug is being developed partly for liver disease.^[3]

Class-level risks to be aware of

As an incretin-based drug, retatrutide shares the theoretical and labeled risks of the approved GLP-1 class (semaglutide, tirzepatide). These have not all been specifically characterized for retatrutide, but a cautious reader should assume they may apply:

• Acute pancreatitis — reported at low rates across the class; persistent severe abdominal pain warrants immediate evaluation.
• Thyroid C-cell tumors — seen in rodent studies with GLP-1 drugs; approved class members carry a boxed warning and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
• Gallbladder disease — rapid weight loss of any kind raises gallstone risk.
• Hypoglycemia (low blood sugar) — uncommon alone, but a real risk when combined with insulin or sulfonylureas.
• Dehydration and kidney strain — usually secondary to severe nausea and vomiting.

Who should not use it, and what to do

Beyond being investigational and unavailable as an approved product, retatrutide would not be appropriate during pregnancy or breastfeeding, in people with a personal/family history of medullary thyroid carcinoma or MEN 2, or in those with significant baseline cardiovascular disease outside a monitored trial. Mild GI symptoms during titration are usually managed by slowing the dose increase, eating smaller lower-fat meals, and staying hydrated. Persistent severe abdominal pain, new palpitations or fainting, or unrelenting vomiting are reasons to stop and seek medical care. For broader context, see Are Peptides Safe? and our peptide side effects overview.

Plain-English takeaway: there is no legitimate consumer source of retatrutide. It is an investigational drug that Eli Lilly distributes only inside clinical trials. Anything sold to the public as "retatrutide" is an unregulated research chemical, and its identity, dose, and purity cannot be assumed.

Legal and regulatory status (2026)

• Not FDA-approved. Retatrutide is investigational and in Phase 3 development as of 2026. There is no approved therapeutic product and no announced brand name.
• Trial-only distribution. Clinical-grade retatrutide exists only within Lilly's trials; it is not available by prescription.
• Research-market material is not the trial drug. Vials sold in "research peptide" channels are unregulated and are not the clinical-grade molecule used in the studies cited on this page. Identity and purity cannot be verified without independent lab testing.

If you are evaluating a research product anyway

We do not recommend using unapproved compounds, but if you are assessing a vendor's material as a matter of research diligence, the same quality signals that apply to any peptide apply here:

• Batch-specific Certificate of Analysis (COA) from an independent lab, showing HPLC purity and mass-spectrometry identity for the exact lot — not a generic sample COA.
• Endotoxin testing for anything intended for injection.
• Proper form and packaging: lyophilized powder in sealed, light-protected vials.
• Red flags: no COA or a manufacturer-only COA, pre-mixed liquid, prices far below market, and any "for human use" or health-claim labeling (which signals non-compliance).

Even a clean COA only tells you what is in the vial — it says nothing about whether using an unapproved drug is safe or wise. For the full legal breakdown, see Are Peptides Legal?

Plain-English takeaway: think of these three as one, two, and three hormone targets. Semaglutide hits one receptor, tirzepatide hits two, retatrutide hits three. In general, adding targets has tracked with more weight loss — but only the first two are FDA-approved with years of safety data behind them. Retatrutide is the most powerful in trials and the least proven in the real world.

Feature	Retatrutide	Tirzepatide	Semaglutide
Receptor targets	GLP-1 + GIP + glucagon	GLP-1 + GIP	GLP-1 only
Highest mean weight loss in trials	~24% (Phase 2, 48 wks, not plateaued)[1]	~21-23% (Phase 3)	~15-17% (Phase 3)
Direct liver-fat effect	Very large (>80%)[3]	Moderate	Modest
FDA status	Investigational (Phase 3)	Approved (Mounjaro/Zepbound)	Approved (Ozempic/Wegovy)
Dosing	Once-weekly injection	Once-weekly injection	Once-weekly injection
Developer	Eli Lilly	Eli Lilly	Novo Nordisk

The weight-loss figures for tirzepatide and semaglutide come from their own separate Phase 3 programs in different populations, so treat cross-drug comparisons as directional rather than as head-to-head proof. The honest bottom line: retatrutide's triple-agonist design produced the largest trial weight loss and by far the largest liver-fat reduction, but it trades that for the least long-term safety data and, so far, a somewhat larger heart-rate signal. For deeper context, see the peptides for weight loss guide and our complete GLP-1 guide.

Related compounds in the pipeline

• Survodutide: a dual GLP-1/glucagon agonist (no GIP) with notable liver-disease activity.
• Mazdutide: another dual GLP-1/glucagon agonist, trialed primarily in China.
• Cagrilintide: an amylin analog studied in combination with semaglutide.
• Liraglutide: the older once-daily GLP-1 agonist and a useful baseline for how far the class has come.